**Journal:**British Journal of Sports Medicine

**Type of article:**Education review

**Preventing overdiagnosis and the harms of too much sport and exercise medicine [Web Version]**

**Authors**

Daniel J Friedman1 and Karim M Khan2

**Affiliations**

1. School of Medicine, Monash University, 27 Rainforest Walk, Monash University Clayton Campus, Wellington Road, Clayton, Victoria, Australia 3800
2. Department of Family Practice and School of Kinesiology, Faculties of Medicine and Education, University of British Columbia, Vancouver, Canada

**Corresponding author**

Daniel Friedman, [ddfriedman@gmail.com](mailto:ddfriedman@gmail.com)

# **Preventing overdiagnosis and the harms of too much sport and exercise medicine**

Do I really need this test, treatment or procedure? What are the downsides? What happens if I do nothing? And are there simpler, safer options?

These four questions, promoted by [Choosing Wisely Canada](https://choosingwiselycanada.org/), featured prominently at the two 2018 conferences, [Too Much Medicine](http://too-much-medicine.com/)  in Helsinki, Finland (Fig. 1), and the 6th Annual Preventing Overdiagnosis in Copenhagen, Denmark. Over 600 of the world’s leading researchers and thinkers in preventing overdiagnosis came together for two weeks in August to highlight the problems caused by medical excess and to identify evidence-informed practices that could wind back the harms of too much medicine.

This education review aims to bring the sport and exercise medicine reader up to date on this topic.

Figure 1. You can review highlights from the Too Much Medicine symposium on Twitter [@toomuchmed](https://twitter.com/TooMuchMed)

Too many people are being overdiagnosed, leading to overtreatment and wasted resources that could be better spent preventing or treating genuine illness(1).While debates about its definition continue**,** narrowly defined, overdiagnosis refers to deviations, abnormalities, risk factors, and pathologies that would never cause symptoms or early death(2). It relates to problems of overmedicalisation and disease mongering, resulting in what one keynote speaker described as a ‘tsunami of overtreatment’.

It is no wonder that an estimated one fifth of healthcare spending across developed countries may be being wasted, equivalent to $1.2tr (£950bn; €1.1tr) or five times the annual spending of the UK National Health Service(3).

Figure 2. Mapping the drivers of overdiagnosis to possible solutions. COI=conflict of interest; OD=overdiagnosis; OU=overuse (first published in BMJ) (4)

As a review in The BMJ discovered(4) (Fig. 2), many factors drive overdiagnosis and cause harm, including cultural beliefs that ‘more is better’, financial incentives, expanding disease definitions and lowering treatment thresholds. While clinicians have been, and will forever be, challenged to balance Hippocratic notions of beneficence and nonmaleficence, the scales are heavily tipped by the underlying influence of industry – such as Big Pharma, divisions of the media more interested in promotion than journalism, and medical journals serving professional rather than public interest. Attempting to summarise discussions at these recent conferences, we saw three specific problems: (1) Vested interests have too often replaced the best interests of patients. (2) Clinicians are being misinformed by flawed guidelines. (3) A lack of systemic transparency (regarding funding, impact, and outcomes) is restricting clinicians in providing the best quality care for patients. Pollution, whether intentional or not, occurs at multiple points in the flow of healthcare information.

Here we introduce three themes from the conferences. BJSM has published papers relating to these issues already(5-10).

## *You’re sick, you just don’t know it yet*

‘What is disease’ may seem like an elementary question, perhaps taught on day one of medical school, yet defining disease and its absence proves to be a circular, slippery slope (Fig. 3). The World Health Organization’s definition of health as “a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity”(11) ignores that our perceptions of health and disease are context-dependent and change over time. At what point in their lives has anyone been ‘completely’ healthy?

Disease can refer to “a combination of signs and symptoms, phenomena associated with a disorder of function or structure or illness associated with a specific cause”(12). There are, however, no universally accepted criteria for defining disease, and so how do we differentiate ‘real’ diseases from human behaviours or experiences that happen to be ‘abnormal’ or unpleasant? We don’t.

Figure 3. Disease implies the converse of ‘complete’ health (whatever that means!)

Consider low back pain (LBP) - the number one cause of disability worldwide, which accounts for 83 million years lived with disability each year (13). More than 80% of us will experience an episode of LBP during our lives(14). But is LBP a disease? Or is it in fact a symptom? LBP can flag serious pathology, such as malignancy or infection, but for most individuals it is a benign problem without specific aetiology. Over 90% of individuals who experience LBP recover within a few months(15) and most who consult their doctor or physiotherapist will experience no clinical benefit from receiving a diagnostic label. If ‘labelled’, they are more likely to adopt the sick role and to suffer costly invasive treatments (e.g., spinal implants) that have questionable value (Fig. 4). Misinformation, medication abuse, focus on pain rather than function and overreliance on radiological imaging and specialist referrals are all contributing factors to overdiagnosis and subsequent overtreatment of LBP(16).

Figure 4. What is driving the rising prevalence of chronic low back pain?

Medicalising ordinary life can be described as **disease mongering** – that is, widening the boundaries of treatable illness to expand markets to sell medication and provide medical procedures/services. In what one speaker described as ‘the corporate construction of disease’(17), Big Pharma sponsors disease definitions (e.g. Allergan and dry eyes(18); GSK and heartburn; GSK and restless leg syndrome) and promotes them to both prescribers and patients (Fig. 5). By magnifying all aspects of an ordinary ailment, upgrading mild symptoms to severe, and marketing risk as disease, disease mongering can augment population-wide fear and infect the healthy with lasting perceptions of ill-health.

Figure 5. Disease branding helps establish a condition as legitimate and serious

**Expanded disease definitions** and **lowered diagnostic thresholds** means that it will soon be possible for everyone to be sick and require pharmacological intervention. If changes to recent guidelines highlighted at the conferences are any indication, it will not be long before pre-hypertension and pre-diabetes are preceded by pre-pre-hypertension and pre-pre-diabetes, and every one of us are categorised into a class of disease severity. According to the new American College of Cardiology/American Heart Association hypertension guidelines(19), one in every two American adults will soon be classified as having high blood pressure. All-encompassing diagnostic criteria enable healthy people to be labelled with life-long disease, encouraging the treatment of the ‘worried well’ and the over-utilisation of finite medical resources.

## *If you’re not sick, you just haven’t had enough tests*

Thanks to rapid technological advances, we are increasingly able to find cancers, abnormal anatomy, and risk factors for disease such as elevated blood pressure or cholesterol. Screening helps reveal low-risk abnormalities earlier, long before they cause symptoms or require treatment (if at all). While the overdiagnosis of breast, prostate and thyroid cancers through screening are common examples, there are similar concerns with musculoskeletal imaging (Fig. 6).

Imaging asymptomatic knees, shoulders and backs without indications of serious underlying pathology can lead to costly incidental findings, or ‘incidentalomas’ (a neologism combining the term ‘incidental’ [benign] and common tissue pathology suffix ‘oma’). While few coincidental diagnoses may be beneficial, many findings lead to unnecessary anxiety and a cascade of clinical follow up (Fig. 7). For example, the increase in the prevalence of femoroacetabular impingement (FAI) and subsequent ‘corrective’ surgeries may be explained by the greater sensitivity of MRI compared to plain radiography in identifying changes that characterize FAI, even in young, pain-free athletes(20).

The more we test, the more we will find.

Figure 6. Prof Paul Glasziou, a former Director of the Centre for Evidence-Based Medicine in Oxford, currently at Bond University in Australia, explaining the consequences of screening programs and unnecessary imaging during his keynote at Preventing Overdiagnosis 2018.

Figure 7. The Ottawa Ankle Rules can help clinicians determine whether a patient with foot or ankle pain should undergo X-rays to diagnose a possible fracture, and reduce costly, unnecessary imaging.

## *A pill for every ill*

Physicians are armed with a prescription pad, so they tend to prescribe medication. Surgeons are equipped with a scalpel, so they operate. Give us a hammer and everything looks like a nail. We all start medical school with a goal to help people, and so when the potential opportunity arises, we use the tools we have to intervene. ‘I can or I *must* fix it’ is a learned response from years of studying abnormal pathology and pharmacological mechanisms of action. The real question is: Why are we not taught that doing nothing is sometimes the best approach? And whatever happened to watchful waiting or conservative management?

Big Pharma promises a pill for every ill, and medical device companies provide a tool for every procedure. We note that for federal government approval (e.g. Food and Drug Administration) devices have a lower bar to reach than do medications because they’re regulated under a different law. Magic bullets and quick fixes are much easier to sell than physical activity, nutrition, mindfulness and other unattractive lifestyle interventions – all lumped together in the last 30 seconds of a 15 minute consultation while the patient is getting up to walk out the door.

Figure 8. Do you really need that MRI or knee scope?

The topic of many presentations at the conferences, [*Choosing Wisely*](http://www.choosingwisely.org/) is a campaign that aims to engage doctors and patients in decisions about potentially unnecessary medical tests, treatments, and procedures (Fig. 8). It started in the USA in 2012 and has since expanded internationally. The initiative encourages medical specialty societies ([sport and exercise medicine included](https://choosingwiselycanada.org/sport-exercise-medicine/)) to identify five tests and procedures that could potentially be avoided to reduce the harms of too much medicine.

Orthopaedic surgery received some heavy criticism at the conferences and many speakers were quick to highlight the unnecessary procedures that continue to be performed on trusting patients. It has already been over 15 years since we found out that for patients with osteoarthritis of the knee, arthroscopic lavage or debridement are no better than placebo(21). More recently, Professor Teppo Järvinen ([@shamteppo](https://twitter.com/shamteppo)), the Chair of this year’s Too Much Medicine symposium, and his research team also demonstrated the lack of efficacy of common surgical procedures for degenerative meniscal tears(22) and shoulder impingement(23). As more than 600 conference attendees found out, a surgical fix does not always fix the problem.

## An uphill battle

Professor Allen Frances, an American psychiatrist known for chairing the task force that produced the fourth revision of the Diagnostic and Statistical Manual (DSM-IV), framed the uphill battle against too much medicine as a “David vs Goliath story”. The forces that benefit from maintaining and increasing overdiagnosis have seemingly endless resources to promote it, and the relative few supporting evidence-based best practice have pocket money in comparison. And while overdiagnosis may be the most important story in health today, it struggles to find its way onto the front pages. We need to amplify and disseminate the conferences’ important messages beyond the echo chamber of academic circles. We need to work out how to fire the slingshots, because “the goliath is very big and we are awfully small”.

Several major medical journals have dedicated special editions solely to articles discussing the harms of too much medicine, such as The BMJ’s [Too Much Medicine Campaign](https://www.bmj.com/too-much-medicine) and JAMA’s Internal Medicine’s [Less is More series](https://jamanetwork.com/collections/44045/less-is-more). There are [books](https://www.goodreads.com/book/show/847591.Selling_Sickness), [podcasts](https://soundcloud.com/therecodo) and even annual conferences (Fig 9)…yet efforts to reduce overdiagnosis are still hindered by clinicians’ and patients’ lack of awareness of the problem.

We must all play our part to prevent overdiagnosis. Clinicians can start by:

* embracing a healthy dose of scepticism and taking a more questioning approach to healthcare.
* adopting more thoughtful management approaches and referral practices that empower patients to engage in shared decision making based on the best available evidence.
* advocating for more transparent healthcare systems (funding, impact, and outcomes) and models that do not promote fee-for-service.

Because when it comes to medicine, sometimes *less is more*.

Figure 9. Save the date: The 7th international Preventing Overdiagnosis conference [#PODC2019](https://twitter.com/search?q=%23PODC2019%20&src=typd) will be in Sydney, 5-7 December 2019

Acknowledgement: Thanks to Dr Ray Moynihan for comments on a draft of this manuscript.

# **Additional Resources**

## Books

Moynihan R, Cassels A. Selling Sickness: How the World's Biggest Pharmaceutical Companies Are Turning Us All Into Patients. Nation Books, 2006

Brownlee S., Overtreated: why too much medicine is making us sicker and poorer. Bloomsbury, 2007

Moynihan R, Mintzes B. Sex, Lies and Pharmaceuticals. Greystone Books, 2010

Welch G, Schwartz L, Woloshin S. Overdiagnosed: Making people sick in pursuit of health, Beacon Press, Boston, 2011

Brawley O. How we do harm: a doctor breaks ranks about being sick in America. St. Martins Press, 2012

Cassels A. Seeking Sickness: Medical screening and the misguided hunt for disease. Greystone Books, 2012

## Podcasts

The Recommended Dose with Ray Moynihan - <https://australia.cochrane.org/trd>

Big Ideas: Too Much Medicine with Dr Iona Heath - <http://www.abc.net.au/radionational/programs/bigideas/iona-heath_too-much-medicine/6947244>

BJSM: Preventing overdiagnosis in 2018 - <https://soundcloud.com/bmjpodcasts/preventing-overdiagnosis-in-2018-with-dr-ray-moynihan-episode-350>

BMJ: Preventing overdiagnosis 2018 (part 1) - <https://soundcloud.com/bmjpodcasts/preventing-overdiagnosis-2018-part-1>

## Videos

Choosing Wisely - <https://www.youtube.com/watch?v=FqQ-JuRDkl8>

TEDxByronBay - Ray Moynihan - Too Much Medicine - <https://www.youtube.com/watch?v=6E-vIuyEeuU&t=904s>

A new epidemic: Motivational Deficiency Disorder - <https://www.youtube.com/watch?v=RoppJOtRLe4&t=72s>; <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1420696/>

## Websites

Too Much Medicine - <http://too-much-medicine.com/>

Preventing Overdiagnosis - <https://www.preventingoverdiagnosis.net/>

BMJ’s Too Much Medicine Campaign - <https://www.bmj.com/too-much-medicine>

JAMA’s Less is More series <https://jamanetwork.com/collections/44045/less-is-more>

Choosing Wisely - <http://www.choosingwisely.org/>

# **References**

1. Moynihan R, Doust J, Henry D. Preventing overdiagnosis: how to stop harming the healthy. BMJ. 2012;344.

2. Brodersen J. Overdiagnosis: An Unrecognised and Growing Worldwide Problem in Healthcare. SJPH. 2017;56(3):147-9.

3. Chalkidou K, Appleby J. Eliminating waste in healthcare spending. BMJ. 2017;356.

4. Pathirana T, Clark J, Moynihan R. Mapping the drivers of overdiagnosis to potential solutions. BMJ. 2017;358.

5. O’Keeffe M, George SZ, O’Sullivan PB et al. Psychosocial factors in low back pain: letting go of our misconceptions can help management. Br J Sports Med. 2018.

6. O’Sullivan K, Darlow B, O’Sullivan P et al. Imaging for hip-related groin pain: don’t be hip-notised by the findings. Br J Sports Med. 2018;52(9):551-2.

7. Malhotra A, Maughan D, Ansell J et al. Choosing Wisely in the UK: reducing the harms of too much medicine. Br J Sports Med. 2016;50(13):826-8.

8. O’Sullivan K, Grunau GL, Forster BB et al. I know what the imaging guidelines say, but…. Br J Sports Med. 2017.

9. Darlow B, Forster BB, O'Sullivan K et al. It is time to stop causing harm with inappropriate imaging for low back pain. Br J Sports Med. 2017;51(5):414-5.

10. Järvinen TLN. Labelling people as ‘High Risk’: A tyranny of eminence? Br J Sports Med. 2016;50(2):77-8.

11. Grad FP. The Preamble of the Constitution of the World Health Organization. Bulletin of the World Health Organization. 2002;80(12):981-4.

12. Campbell EJM, Scadding JG, Roberts RS. The concept of disease. BMJ. 1979;2(6193):757-62.

13. Murray CJ, Vos T, Lozano R et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223.

14. Rubin DI. Epidemiology and risk factors for spine pain. Neurol Clin. 2007;25(2):353-71.

15. Carey TS, Garrett J, Jackman A et al. The outcomes and costs of care for acute low back pain among patients seen by primary care practitioners, chiropractors, and orthopedic surgeons. The North Carolina Back Pain Project. N Engl J Med. 1995;333(14):913-7.

16. Hrudey WP. Overdiagnosis and overtreatment of low back pain: Long-term effects. JOR. 1991;1(4):303-12.

17. Moynihan R, Heath I, Henry D. Selling sickness: the pharmaceutical industry and disease mongering. BMJ : British Medical Journal. 2002;324(7342):886-91.

18. Schwartz LM, Woloshin S. A clear-eyed view of restasis and chronic dry eye disease. JAMA Internal Medicine. 2018;178(2):181-2.

19. Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2018;71(19):e127-e248.

20. Yépez AK, Abreu M, Germani B et al. Prevalence of femoroacetabular impingement morphology in asymptomatic youth soccer players: magnetic resonance imaging study with clinical correlation. Revista Brasileira de Ortopedia (English Edition). 2017;52:14-20.

21. Moseley JB, O'Malley K, Petersen NJ et al. A Controlled Trial of Arthroscopic Surgery for Osteoarthritis of the Knee. N Engl J Med. 2002;347(2):81-8.

22. Sihvonen R, Paavola M, Malmivaara A et al. Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear. N Engl J Med. 2013;369(26):2515-24.

23. Paavola M, Malmivaara A, Taimela S et al. Subacromial decompression versus diagnostic arthroscopy for shoulder impingement: randomised, placebo surgery controlled clinical trial. BMJ. 2018;362.